TY - JOUR
T1 - Fe3O4-Au core-shell nanoparticles as a multimodal platform for in vivo imaging and focused photothermal therapy
AU - Caro, Carlos
AU - Gámez, Francisco
AU - Quaresma, Pedro
AU - Páez-Muñoz, Jose María
AU - Domínguez, Alejandro
AU - Pearson, John R.
AU - Pernía Leal, Manuel
AU - Beltrán, Ana M.
AU - Fernandez-Afonso, Yilian
AU - De La Fuente, Jesús M.
AU - Franco, Ricardo
AU - Pereira, Eulália
AU - García-Martín, Maria Luisa
N1 - info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04378%2F2020/PT#
info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F50006%2F2020/PT#
CTQ2017-86655-R
BIO2017-84246-C2-1-R
PY - 2021/3/20
Y1 - 2021/3/20
N2 - In this study, we report the synthesis of gold-coated iron oxide nanoparticles capped with polyvinylpyrrolidone (Fe@Au NPs). The as-synthesized nanoparticles (NPs) exhibited good stability in aqueous media and excellent features as contrast agents (CA) for both magnetic resonance imaging (MRI) and X-ray computed tomography (CT). Additionally, due to the presence of the local surface plasmon resonances of gold, the NPs showed exploitable “light-to-heat” conversion ability in the near-infrared (NIR) region, a key attribute for effective photothermal therapies (PTT). In vitro experiments revealed biocompatibility as well as excellent efficiency in killing glioblastoma cells via PTT. The in vivo nontoxicity of the NPs was demonstrated using zebrafish embryos as an intermediate step between cells and rodent models. To warrant that an effective therapeutic dose was achieved inside the tumor, both intratumoral and intravenous routes were screened in rodent models by MRI and CT. The pharmacokinetics and biodistribution confirmed the multimodal imaging CA capabilities of the Fe@AuNPs and revealed constraints of the intravenous route for tumor targeting, dictating intratumoral administration for therapeutic applications. Finally, Fe@Au NPs were successfully used for an in vivo proof of concept of imaging- guided focused PTT against glioblastoma multiforme in a mouse model.
AB - In this study, we report the synthesis of gold-coated iron oxide nanoparticles capped with polyvinylpyrrolidone (Fe@Au NPs). The as-synthesized nanoparticles (NPs) exhibited good stability in aqueous media and excellent features as contrast agents (CA) for both magnetic resonance imaging (MRI) and X-ray computed tomography (CT). Additionally, due to the presence of the local surface plasmon resonances of gold, the NPs showed exploitable “light-to-heat” conversion ability in the near-infrared (NIR) region, a key attribute for effective photothermal therapies (PTT). In vitro experiments revealed biocompatibility as well as excellent efficiency in killing glioblastoma cells via PTT. The in vivo nontoxicity of the NPs was demonstrated using zebrafish embryos as an intermediate step between cells and rodent models. To warrant that an effective therapeutic dose was achieved inside the tumor, both intratumoral and intravenous routes were screened in rodent models by MRI and CT. The pharmacokinetics and biodistribution confirmed the multimodal imaging CA capabilities of the Fe@AuNPs and revealed constraints of the intravenous route for tumor targeting, dictating intratumoral administration for therapeutic applications. Finally, Fe@Au NPs were successfully used for an in vivo proof of concept of imaging- guided focused PTT against glioblastoma multiforme in a mouse model.
KW - Contrast agent
KW - CT
KW - Imaging-guided therapy
KW - MRI
KW - Multimodal imaging
UR - http://www.scopus.com/inward/record.url?scp=85103130942&partnerID=8YFLogxK
U2 - 10.3390/pharmaceutics13030416
DO - 10.3390/pharmaceutics13030416
M3 - Article
C2 - 33804636
AN - SCOPUS:85103130942
SN - 1999-4923
VL - 13
JO - Pharmaceutics
JF - Pharmaceutics
IS - 3
M1 - 416
ER -